학술논문
Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial
Document Type
Article
Author
Smith, J.A.; Kitt, M.M.; Wu, W.-C.; Xu, Z.J.; Muccino, D.R.; Ford, A.P.; Morice, A.H.; Birring, S.S.; McGarvey, L.P.; Sher, M.R.; Li, Y.-P.; Birring, S.; Hull, J.; Carr, W.W.; Goldsobel, A.B.; Gross, G.N.; Holcomb, J.R.; Hussain, I.; Sher, M.; Spangenthal, S.; Storms, W.; Morice, A.; Elkayam, D.; Steven, G.C.; Krainson, J.; Fakih, F.A.; Matz, J.; Brooks, G.D.; Casale, T.; Berman, G.D.; Condemi, J.J.; Greos, L.S.; Gogate, S.U.; Sher, E.R.; Friesen, J.H.; Schenkel, E.J.; Bernstein, D.I.; Corren, J.; Sundar, K.; Gotfried, M.H.; Montanaro, A.; Lumry, W.R.; Amar, N.J.; Kaplan, M.S.; Prenner, B.M.; Murphy, T.R.; Good, J.S.; Parker, S.; Harrison, T.; Pavord, I.; Brightling, C.; Djukanovic, R.; McQuaid, D.; Denenberg, M.; Ettinger, N.A.; Iyer, V.
Source
In: The Lancet Respiratory Medicine . (The Lancet Respiratory Medicine, August 2020, 8(8):775-785)
Subject
Language
English
ISSN
22132619
22132600
22132600